• Online anaphylaxis training
  • Information for health professionals
  • aifa-grants
  • 5 things to question

  • ASCIA 2016 Conference – registration and abstract submission is now open
    May 25, 2016:  It is a pleasure to advise that the ASCIA 2016 Conference website now has available:  conference program;  discounted earlybird registration until 15 July 2016;  abstract submission open until 18 July 2016;  accommodation booking.  Quick links to key pages:  Conference prog...
  • ASCIA releases guidelines for infant feeding and allergy prevention
    May 18, 2016: ASCIA Guidelines for infant feeding and allergy prevention and information on how to introduce solid foods to infants have been released on the ASCIA website: www.allergy.org.au/patients/allergy-prevention  These guidelines provide parents and health professionals with advice and recommendations relevant ...
  • Federal Government announces funding of $500k for National Allergy Strategy implementation
    May 16, 2016:  It is with great pleasure that we confiirm that the federal government's funding of $500k for National Allergy Strategy implementation was announced at the launch of Food Allergy Week in Sydney on 16 May 2016, by the Minister for Health, the Hon Sussan Ley MP. The National Allergy Strategy was launched...
  • Updated information regarding the status of allergen shortages in Australia and New Zealand
    May 2, 2016:  ASCIA was officially advised on April 29 that there is a preventive recall of the Inmunotek brand of subcutaneous (injectable) immunotherapy allergen extracts that are supplied by Australasian Medical and Scientific Limited (AMSL). This preventive recall means that shipping of these products from the AMSL warehouses is...
  • Changes to adrenaline autoinjector labels
    Apr 19 2016:  In Australia, adrenaline is the approved name of the ingredient in autoinjector devices used for the emergency treatment of anaphylaxis. Currently, the only available autoinjector to treat anaphylaxis in Australia and New Zealand is supplied under the brand name EpiPen®. In some countries, including the USA, adrenaline...
  • How are you managing your pollen allergies in a changing global climate?
    Apr 5 2016:  Data shows that global warming has resulted in plants producing more pollen. The allergy season is lengthening as well as the prevalence and severity of symptoms for people suffering from allergic rhinitis caused by pollen allergy, commonly referred to as hay fever.   World Allergy Week An init...
  • Primary immunodeficiency (PID) e-training
    Mar 9, 2016:  New e-training course online now.  ASCIA primary immunodeficiency (PID) e-training for health professionals is now available free of charge from the ASCIA website: www.allergy.org.au/health-professionals/health-professionals-e-training  The main objectives of this course are to: Increase awareness of P...
  • ASCIA anaphylaxis e-training for Victorian Schools is now online
    Feb 22, 2016:  ASCIA has worked with the Victorian Education Department over the past 18 months to develop ASCIA anaphylaxis e-training for Victorian schools. This course is now available at https://etrainingvic.allergy.org.au/  With most Australian states using ASCIA e-training as the recommended training, the majority of sch...
  • Information regarding the status of allergen shortages in Australia and New Zealand
    Jan 12, 2016:  Issues surrounding supply of allergen extracts are outside the control of ASCIA or individual medical practitioners. Information provided at the time of writing this is subject to change, and is derived from the primary source of information, Stallergenes Australia. ASCIA Information regarding the status of allergen...
ASCIA is a WAO member society

ASCIA is a WAO member society
Follow ASCIA

ASCIA on facebookASCIA on TwitterASCIA on YouTube

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Disclaimer and Privacy

The ASCIA website is intended for use by ASCIA members, other health professionals, the general public and media. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...


Sponsors and Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites.

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.


This website is certified by Health On the Net Foundation. Click to verify.This site complies with the
HONcode standard for
trustworthy health

Verify here.